Clinical Trial Update: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas [Phase 2]

View source ↗

Summary

A Phase II study evaluating the combination of eribulin and pembrolizumab in soft tissue sarcomas has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leiomyosarcoma
• Liposarcoma
• Soft Tissue Sarcoma
• Undifferentiated Pleomorphic Sarcoma

Drugs mentioned

• Halaven (eribulin)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Sarcoma, Liposarcoma | Phase 2 | Status: COMPLETED | Results posted: 2025-08-28